Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lost Patent Protection? Move To China, Says Specialty Biotech SciClone

This article was originally published in PharmAsia News

Executive Summary

The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company

You may also be interested in...



Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China

Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.

Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China

Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.

SciClone Takes Deeper Plunge In China Following Solid Q1 Results

SciClone sees more opportunities ahead as it plans deeper expansion into China, following Q1 results that posted a 38% increase in sales for its lead product.

Related Content

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel